Rationale: There are conflicting reports describing the effect of macrolide resistance on the presentation and outcomes of patients with Streptococcus pneumoniae pneumonia.
Streptococcus pneumoniae is identified in 20-60% of patients requiring hospitalization for community-acquired pneumonia (CAP), making it the leading cause of CAP (1) (2) (3) , and in 5.5-49% of patients hospitalized for healthcareassociated pneumonia (HCAP) (1, 4, 5) . The mortality of patients with S. pneumoniae pneumonia ranges from 6.4% in outpatients and in hospitalized patients who do not require treatment in an intensive care unit (ICU) to more than 35% in those requiring treatment in the ICU (6) .
Current Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) guidelines recommend a macrolide antibiotic (azithromycin, clarithromycin, or erythromycin) as first-line therapy for previously healthy patients who have no risk factors for drug-resistant S. pneumoniae infection (strong recommendation; level I evidence) and a combination of a macrolide and a b-lactam for patients who require hospitalization but not in the ICU. In patients with CAP who require ICU admission the guideline recommends using a combination of a b-lactam plus macrolide or a fluoroquinolone (5) .
The prevalence of macrolide resistance in S. pneumoniae is increasing with recent rates ranging from 18 to 35% (7) (8) (9) (10) (11) . Although some studies link macrolide resistance with treatment failure in community-acquired respiratory tract infections (12) (13) (14) , the effect of having macrolide-resistant S. pneumoniae on clinical outcomes of patients with pneumonia has not been clearly established. We performed a retrospective observational study of prospectively collected data to examine the effect of macrolide resistance on the outcomes of patients who were hospitalized for pneumonia caused by S. pneumoniae.
Methods Ethics Statement
The study was approved by the Ethics Committee of the Hospital Clinic of Barcelona (Barcelona, Spain; Register: 2009/ 5451). Written informed consent was waived because of the noninterventional design.
Study Design and Patients
This was a retrospective observational study of data that were prospectively collected in the Hospital Clinic of Barcelona. Subjects included all adults admitted with S. pneumoniae pneumonia from January 1, 2000 to December 31, 2013, including those coming from nursing homes.
Pneumonia was defined as the presence of a new infiltrate on a chest radiograph together with clinical symptoms that were suggestive of lower respiratory tract infection (e.g., fever, cough, sputum production, pleuritic chest pain). We excluded patients who were receiving an immunosuppressant, those taking more than 10 mg/day of prednisone, or cytotoxic therapy, and all patients known to have human immunodeficiency virus infection.
Data Collection and Evaluation
At the time of hospital admission we recorded the patients' age, sex, smoking history, alcohol use, illicit drug consumption, comorbidities, antibiotic treatment in the previous 30 days before hospital admission, whether they were receiving inhaled or systemic corticosteroids, clinical symptoms and signs, arterial blood gases, chest radiograph findings, a variety of laboratory tests, the results of diagnostic procedures (see later), the pneumonia severity index and CURB-65 score (consciousness, urea, respiratory rate, blood pressure, 65 year old) (15, 16) , and the initial antibiotic therapy.
Over the course of their hospitalization we recorded the length of hospital stay and the 30-day in-hospital mortality, and whether the patients required noninvasive and/or invasive ventilatory support, had any pulmonary complications, defined as multilobar infiltration, pleural effusions, or meeting criteria for the acute respiratory distress syndrome (17) , or developed septic shock or acute renal failure.
Microbiologic Evaluation and Diagnostic Criteria
All patients had microbiologic examination of expectorated sputum, urine, two samples of blood, and nasopharyngeal swabs. Those who underwent a thoracentesis, intubation, or bronchoscopy also had microbiologic examination of the pleural fluid, tracheobronchial aspirates, and/or bronchoalveolar lavage. Sputum and blood samples were obtained in the emergency department for bacterial culture before starting antibiotic therapy. Nasopharyngeal swabs were processed for respiratory virus detection. Urine was sent for S. pneumoniae and Legionella pneumophila antigen assessment within 24 hours after hospital admission. Sputum testing included Gram and Ziehl-Neelsen staining and culturing for bacterial, fungal, and mycobacterial pathogens. Blood samples for serology of atypical pathogens and respiratory viruses were collected at admission and between the third and sixth week thereafter.
For the purpose of this study patients were considered to have S. pneumoniae pneumonia if S. pneumoniae was cultured from the blood, pleural fluid, tracheobronchial aspirates (at >10 5 CFU/ ml) or bronchoalveolar lavage (at >10 4 CFU/ml), or from sputum using standard microbiologic methods.
Strains Appropriateness of empiric antibiotic treatment was defined according to IDSA/ ATS guidelines for management of CAP and HCAP (5, 18) .
Statistical Analysis
We report the mean and SD for continuous variables with normal distribution and the median (first quartile-third quartile) for those with nonnormal distribution and compared them using the t test or the nonparametric Mann-Whitney test, respectively. Categorical variables are presented as number of patients (percentage) and were compared using the chi-square test or Fisher exact test. All reported P values are two sided and not adjusted for multiple comparisons. A P value less than 0.05 was considered significant. All analyses were performed with IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY).
Results

Demographic and Clinical Variables on Presentation
During the study period 5,878 patients were hospitalized with a diagnosis of CAP. Of these, 643 had one or more microbiologic studies that were positive for S. pneumoniae and 139 (22%) of these were macrolide resistant ( Figure 1 , Table 1 ). Their demographics and clinical characteristics are presented in Table 2 . Because only 12 (1.8%) patients had intermediate resistance to macrolides their results were pooled with the 127 who had high level of resistance.
Outcomes
By univariate analysis patients with macrolide-resistant S. pneumoniae pneumonia were more likely to have received antibiotics within the previous 30 days and more likely to have chronic obstructive pulmonary disease. Patients with macrolideresistant disease were less likely to have fever, bacteremia, pulmonary complications, or shock (Table 3 ) and were also less likely to require noninvasive ventilation (although the number of patients receiving noninvasive ventilation was too small for a meaningful comparison). We found no suggestion that patients with macrolide-resistant S. pneumoniae pneumonia presented with more severe disease or had worse clinical outcomes regardless of whether we did or did not exclude patients who died within the first 3 days of admission (Table 4) or if we restricted the analysis exclusively to patients with invasive disease (i.e., bacteremia and/or empyema) (see Table E1 in the online supplement).
Outcomes Related to Antibiotic Treatment
Surprisingly, 129 patients (20%) were treated with a single antibiotic, a regimen that would be inconsistent with IDSA/ATS guidelines for treating hospitalized patients with either CAP or HCAP (Table 5) . Despite this, we found no suggestion that patients receiving treatment that was inconsistent with these guidelines had worse clinical outcomes (Table 6 ). Of the 104 patients with macrolide-resistant S. pneumoniae pneumonia, 71 (68%) received a dual antibiotic regimen that included a macrolide and 33 (32%) did not. Despite their regimen containing only one antibiotic to which their organism was resistant, we found no difference in the outcomes of patients with macrolide-resistant versus macrolide-sensitive S. pneumoniae pneumonia (Table 7) , with the exception that the frequency of ICU admission was higher in patients receiving dual therapy that did not include a macrolide.
Discussion
The important findings of this study are that we could find no evidence of more severe ORIGINAL ARTICLE presentations or worse clinical outcomes in patients who were admitted to the hospital with roentgenographically proven pneumonia caused by S. pneumoniae pneumonia as a function of whether the organisms cultured were sensitive or resistant to macrolide antibiotics or if the patients had invasive or noninvasive disease. We also found no evidence of worse clinical outcomes in patients who were treated with regimens that were consistent versus inconsistent with current guidelines for treating CAP or HCAP. Literature on the effect of macrolide resistance on outcomes of patients with S. pneumoniae infections is conflicting. Twenty years ago Moreno and colleagues (19) found no difference in hospital mortality in patients with macrolidesensitive versus -resistant S. pneumoniae (14% vs. 18% in those with macrolidesensitive and -resistant infections, respectively; P = 0.8). Two subsequent studies found trends toward an increased mortality in patients with macrolideresistant pneumococcal disease that were not statistically significant (20, 21) but Song and colleagues (22) did not (P = 0.6 or 0.9 for patients with pneumonia severity index 1-5 and 4 or 5, respectively). In an observational study Asadi and colleagues (23) found that outpatients with CAP had a lower mortality if they were treated with regimens that were consistent with published guidelines compared with those whose regimens were not (6% vs. 1%, respectively; odds ratio, 0.23; 95% confidence interval, 0.09-0.59; P = 0.002). Within the group receiving treatment that was concordant with guidelines, those receiving macrolides were less likely to die within 30 days (64% vs. 0.2%; odds ratio, 2.3; 95% confidence interval, 0.09-0.86; P = 0.03). Other observational studies also find that mortality is lower in inpatients with CAP and pneumococcal bacteremia who are treated with macrolides (21, 24, 25) but no benefit was seen if data are restricted to randomized controlled trials (24) . Baddour and colleagues (26) found no difference in the mortality of patients treated with combination antibiotic therapy versus monotherapy unless the patients were critically ill. We found that patients hospitalized with S. pneumoniae pneumonia who were treated with guideline-compliant regimens had lengths of hospital stay than those treated with regimens that were noncompliant but the patients treated with guideline-consistent regimens were more likely to have bacteremia on admission, multilobar infiltration, acute respiratory distress syndrome, and acute renal failure (Table 6) .
Several observational studies and a recent randomized controlled trial have found improved outcomes in patients with CAP if their treatment regimens included a macrolide antibiotic (27) (28) (29) . We found no difference in outcomes in patients whose regimens did or did not include a macrolide ( Table 7) , except that patients with S. pneumoniae resistant to macrolide had less need for ICU admission. This finding opens again the question of the potential antiinflammatory effect of macrolide (30, 31) .
Our study has a number of limitations. First, because the data were collected from a single academic teaching hospital in Spain the results might not generalize to other Percentages are calculated on nonmissing data.
